Purpose: Methylxanthines are commonly used to treat apnea of prematurity. Recent studies have reported that caffeine therapy reduces the rate of bronchopulmonary dysplasia (BPD) and improves the rate of survival in preterm infant without neuro developmental disabilities. This study was performed to compare the effects on apnea episodes, adverse effects and morbidity between the caffeine and theophylline groups. Methods: A retrospective study was performed in 143 infants born at less than 33 weeks of gestation and treated with caffeine (n=54) or theophylline (n=89) from 2011 to 2012. The baseline characteristics of mothers and their infants were examined. The number of apnea events before and after treatment, the duration of respiratory support, and the rate of reintubation were compared. Furthermore, adverse effects, clinical course, and morbidities such as BPD and periventricular leukomalacia were compared before discharge. Results: There were no significant differences in the baseline characteristics. Theo phylline and caffeine appeared to have similar shortterm therapeutic advantages on apnea of prematurity in mean apnea rate after first two weeks of treatment. However, there were no statistically significant differences in the duration of respi ratory support, rate of reintubation, clinical course, and morbidity between the two groups. Adverse effects, indicated by feeding intolerance were lower in the caffeine group. Conclusion: Caffeine was as effective as theophylline in the shortterm for reducing apnea in preterm babies and was better tolerated and was easier to administer. A prospective randomized study is needed to confirm the effect of caffeine on the lone term neuro developmental outcome in prema turity.
INTRODUCTION
Apnea of prematurity (AOP) is a relatively common and troublesome disorder that is caused by developmental immaturity of the respiratory control system itself or by many diseases or pathophysiologic states affecting oxygen transport or ventilation in preterm infants 1) .
Although the definition of apnea is inconsistent, this condition has been most widely defined as cessation of breathing for more than 20 seconds, typically accompanied by bradycardia and/or cyanosis 2) . Persistent uncontrolled apnea may be harmful to the developing brain and organs and requires reintubation and prolonged mechanical ventilation 3) .
The treatment for apnea varies from supportive care such as gentle tactile stimulation or positional change to invasive treat ment such as continuous positive airway pressure (CPAP) or mechanical ventilation. Methylxanthine drugs such as caffeine or theophylline are also used for treating this condition 4, 5) . These drugs increase the central respiratory drive by lowering the threshold of response to hypercapnia as well as enhance con tractility of the diaphragm and prevent diaphragmatic fatigue.
The precise pharmacologic basis for these actions, which are mediated by an increase in respiratory neural output, is still under investigation. A likely major mechanism of action is through competitive antagonism of adenosine receptors, as adenosine acts as an inhibitory neuroregulator in the central ner vous system 69) .
According to the Cochrane Database of Systematic Reviews in 2010 7) , caffeine appears to have similar shortterm effects on apnea/bradycardia as does theophylline, but caffeine has more therapeutic advantages and lower toxicity than theophylline. In addition, caffeine treatment resulted in an increase in the sur vival rate without neurodevelopmental disability and a decrease in the morbidity such as bronchopulmonary dysplasia (BPD) in low birth weight infants 1017) . Although caffeine is widely used, there is no report on the effects of caffeine therapy in Korea because it has been imported recently. The objective of this study was to compare the therapeutic effects, side effects, and morbidity between the caffeine and theophylline groups.
MATERIALS AND METHODS

Subjects
One hundred and seventyone infants born at less than 33 weeks of gestation were admitted to the neonatal intensive care unit of Chonnam National University Hospital from January 2011 to December 2012. Exclusion criteria for study participation were the presence of congenital anomaly (n=3), neuromuscular disease (n=2), severe intraventricular hemorrhage (≥grade III) (n=8), surgical condition (n=8), congenital heart disease (n=5), and death (n=2). Finally, one hundred fortythree infants (82 males and 61 for females) were enrolled in this study. As caffeine therapy was introduced to our hospital in February 2012, the infants treated with caffeine (February 2012 to December 2012) were compared with the infants treated with theophylline (Ja nuary 2011 to January 2012) in terms of baseline characteri stics, effect on apnea episodes, side effects, and morbidity. This study was approved by the institutional review board of Chonnam National University Hospital, and parental consent form was not obtained as the study consisted of retrospective chart review.
Treatment Regimen
Both theophylline (Theoclear ® ) and caffeine (Neocaf ® ) were administered as a therapeutic treatment for AOP. In the theo phylline group, a loading dose of 57 mg/kg of theophylline was administered intravenously for 30 minutes, followed by 1.52 mg/kg every 8 to 12 hours by either the oral or intravenous route.
The purpose was to maintain the therapeutic level at 7 to 12 µg/ mL by monitoring once or twice a week at 0.5 to 1 hour after intravenous administration or 1 to 2 hours after oral administra tion. In the caffeine group, a loading dose of 20 mg/kg of caffeine was administered intravenously for 30 minutes followed by 58 mg/kg intravenously once a day every 24 hours. If apnea persist ed, another dose of 10 mg/kg was administered. The mainten ance dose was increased by 20% and the serum drug concentra tion was not measured. The dosage for intravenous or oral administration of the two drugs was the same, and the drugs were discontinued after the infants reached 34 to 36 weeks of gestation , if apnea events has been absent for 5 to 7 days.
Result Analysis
We compare the baseline characteristics, the effect on apnea events, adverse effects, and morbidity during admission between the caffeine and theophylline groups. RDS was diagnosed based on the clinical signs, microbubble test, and chest radiographic findings 18) . PDA was diagnosed based on the clinical signs or symptoms along with chest radio graphic findings, and the diagnosis was confirmed by echo cardiography 19) . NEC was diagnosed according to the modified Bell's classification (more than stage II) 20) . The criteria for BPD (for neonates treated with more than 21% oxygen for at least 28 days) was as follows. The time point of assessment was 36 weeks' postmenstrual age or discharge to home (whichever comes first) for babies born before 32 weeks and 56 days' postnatal age or discharge to home (whichever comes first) for babies born after 32 weeks gestation 21) . PVL was diagnosed when cranial ultra sound showed cystic changes in the periventricular area, or when brain magnetic resonance imaging (MRI) showed lack of white matter myelin, or a relative growth of ventricle and gray matter due to a decreased volume of white matter 22) .
Statistical Method
Statistical analysis was performed to examine the differences between the caffeine and theophylline groups using SPSS for Windows, version 17.1 (SPSS Inc., Chicago, IL, USA). According to data characteristics, Chisquare test and Student ttest were performed. The results were considered to be statistically signifi cant when the P value was less than 0.05.
RESULTS
Baseline Characteristics
Among the total 143 patients, there were 54 patients in the caffeine group (30 males, 24 females) and 89 patients in the theophylline group (52 males, 37 females). There were no signi ficant differences in maternal age, use of antenatal steroids, pre sence of histologic chorioamnionitis, and Csection rate between the two groups. Furthermore, neonatal birth weight, gestational age, gender, birth place, single or multiple births, and Apgar scores at 1 and 5 minutes showed no significant differ ences between the two groups ( Table 1) .
Therapeutic Effects
The initial day of therapy was 3.5±2.8 days of life in the caffeine group and 2.7±7.9 days in the theophylline group, with no stastically significant difference between the two groups. The total duration of treatment was 30.0±17.4 days in the caffeine group and 29.7±10.1 days in the theophylline group, with no differ ence between the two groups. With respect to the thera peutic effects according to each time period, the number of apnea events per day was 4.0±3.2 before treatment and it was signi ficantly decreased to 2.3±2.1 (P=0.001), 1.9±2.0 (P<0.001), and 1.3±1.6 (P<0.001) after 1 to 3 days, 4 to 7 days, and 8 to 14 days of treatment, respectively in the caffeine group. Also, the However, there were no significant differences between the two groups at each time period (Table 2) .
With respect to assisted respiratory therapy, the duration of 
Adverse Effects
The percentage of patients who experienced feeding diffi culties such as residual volume (more than half of the feeding amount), abdominal distention, regurgitation, or vomiting was 90.6% in the caffeine group and 98.9% in the theophylline group with a statistical significance (P=0.027). The number of episodes of feeding difficulties per patient during drug therapy was 8.4±
6.7 in the caffeine group compared with 11.9±0.6 in the theo phylline group with a statistical significance (P=0.042). Tachy cardia (≥180 beats/min) was noted in 47.2% of patients in the caffeine group and in 50.6% of patients in the theophylline group with no significance. The number of tachycardia events per patient during drug therapy was 1.8±4.0 in the caffeine group and 2.6±9.4 in the theophylline group with no significance.
Neurologic abnormality such as seizure was not noted in the caffeine group, but three patients in the theophylline group de veloped a neurologic abnormality; however, this result was not statistically significant (Table 3 ).
Clinical Course and Morbidity
The initial trophic feeding was started on 2.9±1. During the hospitalization period, there were no significant differences in morbidities such as RDS, PDA, NEC, BPD, and PVL between the two groups (Table 4) .
DISCUSSION
Newborns especially the extremely premature babies encoun ter problems with body temperature regulation, acquisition of proper feeding, and control of respiration within the first few days of life 23) . Although the exact mechanism is not entirely clear, 24, 25) .
The incidence of AOP increases with decreasing gestational age or birth weight. The younger the gestational weeks, the incidence is more prevalent; 7% at 34 to 35 weeks of gestation, 15% at 32 to 33 weeks of gestation, and 54% at 30 to 31 weeks of gestation. Essentially, all infants less than 28 weeks of gestational age or less than 1,000 g of birth weight have AOP 5, 23) . Persistent apnea may be harmful to the developing brain or organs.
Methylxanthines (such as caffeine and theophylline) are drugs that are believed to stimulate breathing and have been used to reduce apnea.
In the Cochrane review in 2010, HendersonSmart and Steer 7) reported that there was no difference in mean apnea rate between the caffeine and theophylline groups after one to three days treatment and five to seven days treatment . No difference in treatment failure rate (less than 50% reduction in apnea/ bradycardia) was found between the caffeine and theophylline groups after one to three days treatment or five to seven days treatment. In our study, there was no difference in the baseline characteristics of mothers and their newborn infants, and the initial day and total duration of drug therapy between the two groups. Compared to before treatment, daily mean apnea rate was significantly decreased until 14 days after treatment in both groups, and there was no difference between the two groups, which was similar to that in a previous report 7) .
Side effects of methylxanthines which lead to changes in doses include tachycardia and signs of gastrointestinal dysfunc tion, including abdominal distention, feeding intolerance, or vomiting. jitteriness, irritability, and seizures may also be seen.
In very low birth weight infants, mild diuresis and urinary calcium excretion occur 2628) . In the Cochrane review in 2010 7) , adverse effects were lower in the caffeine group (summary rela tive risk 0.17, 95% CI 0.04 to 0.72), and theophylline was asso ciated with higher rates of toxicity. Caffeine has several advan tages such as effects similar to those of theophylline on apnea, lesser adverse effects, larger gap between therapeutic and toxic levels, more easy absorption, and longer halflife that allows oncedaily dosing 7) .
In our study, the caffeine group showed a significantly less feeding intolerance than the theophylline group, but there was no significant difference in the postnatal day on which initial trophic feeding and full enteral feeding were started. With respect to neurological problems, seizure was observed in three patients of the theophylline group and in none of the patients of the caffeine group, but this difference was not statistically signi ficant. It could not be confirmed that the seizure was related to theophylline therapy because the serum theophylline concen trations in all three patients with seizure were within their therapeutic ranges.
It is controversial whether RBC transfusion reduces the fre quency of apneic spells in some infants. In a randomized trial, Bell et al. 29) reported that apnea occurred more frequently in the group with limited transfusions. In this study, packed RBC transfusion was considered if the hemoglobin level was less than 10 g/dL or if the hematocrit was less than 30% and the infant had frequent or severe episodes of apnea and bradycardia while respiratory support. There was no significant difference in the number of RBC transfusions between the two groups.
Schmidt et al. 16) conducted a randomized study in preterm infants with birth weight from 500 to 1,250 g during the first 10 days of life and they received either caffeine or placebo; the authors evaluated the shortterm outcomes before the preterm infants were discharge home. In the caffeine treatment group, positive airway pressure was discontinued about 1 week earlier than that in the placebo group (31.0 weeks vs. 32.0 weeks, P< 0.001). Also, among the infants who remained alive at a post menstrual age of 36 weeks, the need for oxygen therapy was less in the caffeine group (36% vs. 47%, P<0.001). The cranial ultra in the caffeine group, and the difference was significant espe cially at two weeks after birth. Also, the frequency of PDA that required medical treatment (29.3% vs. 38.1%, P<0.001), espe cially surgical treatment (4.5% vs. 12.6%, P<0.001) was less in the caffeine group. Our study was a not a placebocontrolled study, but it was a comparative study between the caffeine and theo phylline groups. There were no differences in the duration of assisted respiratory support, the rate of reintubation, and the incidence of PDA, PVL, and BPD during hospitalization between the two groups.
Also, Schmidt et al. 17) studied the longterm effects of caffeine therapy on AOP in infants with birth weights of 500 to 1,250 g at a corrected age of 18 to 21 months. The infants treated with caffeine showed reduced incidences of cerebral palsy (4.4% vs.
7.3%, P=0.009) and cognitive delay (33.8% vs. 38.3%, P=0.04) compared to the placebo group. The rates of death, deafness, and blindness, and the mean percentiles for height, weight, and head circumference at followup did not differ significantly between the two groups. There was no significant difference in the incidence of PVL for predicting the neurodevelopmental outcome between the two groups in our study, and therefore, a more longterm postdischarge followup is needed to assess the neurodevelopmental outcome.
Caffeine is more expensive than theophylline. But it can be used once a day because of its longer half life and does not require periodic monitoring because of its broad therapeutic range 12, 13, 30) . In addition, it reduces the burden of blood sampling and the cost for drug monitoring. Although this is the first comparative study between caffeine and theophylline therapies for AOP in our country, the limitation of this study is that it was a single center retrospective study and the time period was differ ent for the two regimens.
In conclusion, both caffeine and theophylline showed similar effects on apnea events. Caffeine has several advantages such as less feeding intolerance, once a day treatment, no need of drug monitoring, and cost effectiveness. For clarifying its drug effect on longterm neurodevelopmental morbidity such as cerebral palsy, a prospective, multicenter, randomized controlled study comparing each of the two methylxanthines (caffeine or theo phylline) with placebo or caffeine versus theophylline is needed.
